//
Japanese biotechnology firm Mebiopharm is keen to be listed on the market, which was established in 2009 as a joint venture between the Tokyo Stock Exchange and London Stock Exchange.
Designed for professional stock market investors in the Far Eastern country, it has struggled to attract companies until now.
Mebiopharm, which specialises in developing cancer treatment drugs, appointed Singapore-based stock broker Phillip Securities as its advisor for the deal.
Chief executive Tadashi Fujisawa was quoted by the Wall Street Journal as saying: "We selected Tokyo Aim because we found the market attractive due to its flexibility and speediness in various procedures."
Yutaka Ita, chief operating officer of Tokyo Aim, said he believes the move will be a "major trigger" for further investment in the market.
The company was established in July 2002 with ten million yen in capital.
Posted by Greg Secker
